Drug results: 6
| neostigmine | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. |
|
| glycopyrronium bromide | Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect. |
|
| fazadinium | FAZADINIUM BROMIDE was heading 1991-94; was FAZADINIUM see under PYRIDINIUM COMPOUNDS 1979-90; was AH 8165 see under PYRIDINIUM COMPOUNDS 1975-78; AH 8165 was see FAZADINIUM BROMIDE 1979-94; use PYRIDINIUM COMPOUNDS to search FAZADINIUM BROMIDE 1991-94, FAZADINIUM 1979-90 & AH 8165 1975-78; a rapid-acting, short-lasting, competitive nondepolarizing neuromuscular blocking agent; its action is rapidly and completely reversed by neostigmine |
|
| pyridostigmine | A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. |
|
| ambenonium | A quaternary ammonium compound that is an inhibitor of cholinesterase activity with actions similar to those of NEOSTIGMINE, but of longer duration. Ambenonium is given by mouth in the treatment of myasthenia gravis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1112) |
|
| rocuronium | Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. |
|








Citing DrugCentral © 2025.
License